Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry

Zacks06-14

Intellia Therapeutics, Inc. NTLA is developing its lead in vivo genome-editing candidate, NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. The company is collaborating with Regeneron ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2443606711?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24","is_english":true,"pubTime":"2024-06-14 23:49","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2443606711","market":"us","top_or_hot":-1,"title":"Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry","media":"Zacks","content":"<div>\n<p>Intellia Therapeutics, Inc. NTLA is developing its lead in vivo genome-editing candidate, NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. The company is collaborating with Regeneron ...</p>\n\n<a href=\"https://finance.yahoo.com/news/intellia-ntla-banks-genome-editing-154900825.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-14 23:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/intellia-ntla-banks-genome-editing-154900825.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Intellia Therapeutics, Inc. NTLA is developing its lead in vivo genome-editing candidate, NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. The company is collaborating with Regeneron ...</p>\n\n<a href=\"https://finance.yahoo.com/news/intellia-ntla-banks-genome-editing-154900825.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0289739699.SGD","symbol_name":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/intellia-ntla-banks-genome-editing-154900825.html","article_id":"2443606711","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2443606711","pubTimestamp":1718380140,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Intellia Therapeutics, Inc. NTLA is developing its lead in vivo genome-editing candidate, NTLA-2001, for the treatment of transthyretin  amyloidosis. The company is collaborating with Regeneron Pharmaceuticals REGN for the development of NTLA-2001.NTLA-2001 is being studied for two indications: ATTR amyloidosis with polyneuropathy  patients and ATTR amyloidosis with cardiomyopathy  patients. The phase III MAGNITUDE study evaluating NTLA-2001 to treat ATTR amyloidosis with cardiomyopathy is currently ongoing.If the data from the MAGNITUDE study is found to be positive, it will enable global regulatory filings for NTLA-2001.Intellia has received the FDA alignment for a pivotal phase III study design, which will support a biologics license application  filing for NTLA-2001 as a single-dose treatment in ATTRv-PN pending review of its investigational new drug application. The phase III study is likely to begin by 2024-end.NTLA-2001 is part of the company’s co-development and co-promotion ag","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","REGN":"再生元制药公司","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","HAE":"美国血液技术","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","BK4585":"ETF&股票定投概念","BK4556":"基因编辑","BK4139":"生物科技","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4535":"淡马锡持仓","BK4198":"医疗保健用品","BK4588":"碎股","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc","CRSP":"CRISPR Therapeutics AG","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","NTLA":"Intellia Therapeutics Inc","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","ALGS":"Aligos Therapeutics, Inc.","ACRV":"Acrivon Therapeutics, Inc.","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","BK4505":"高瓴资本持仓","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC"},"translate_title":"Intellia(NTLA)在竞争中依靠基因组编辑管道","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALGS":1,"REGN":1,"NTLA":1,"HAE":1,"ACRV":1,"CRSP":0.62},"content_text":"Intellia Therapeutics, Inc. NTLA is developing its lead in vivo genome-editing candidate, NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. The company is collaborating with Regeneron Pharmaceuticals REGN for the development of NTLA-2001.\nNTLA-2001 is being studied for two indications: ATTR amyloidosis with polyneuropathy (ATTRv-PN) patients and ATTR amyloidosis with cardiomyopathy (ATTR-CM) patients. The phase III MAGNITUDE study evaluating NTLA-2001 to treat ATTR amyloidosis with cardiomyopathy is currently ongoing.\nIf the data from the MAGNITUDE study is found to be positive, it will enable global regulatory filings for NTLA-2001.\nIntellia has received the FDA alignment for a pivotal phase III study design, which will support a biologics license application (BLA) filing for NTLA-2001 as a single-dose treatment in ATTRv-PN pending review of its investigational new drug application. The phase III study is likely to begin by 2024-end.\nNTLA-2001 is part of the company’s co-development and co-promotion agreement with Regeneron. While NTLA is the lead party in the deal for NTLA-2001, REGN shares 25% of the development costs and commercial profits.\nThe collaboration with Regeneron has given a boost to the company to develop its pipeline.\nShares of Intellia have declined 14.8% so far this year compared with the industry’s decrease of 5.1%.\nImage Source: Zacks Investment Research\nIntellia’s clinical-stage pipeline comprises another gene-editing candidate, NTLA-2002, which is currently being developed for treating hereditary angioedema (HAE). Earlier this month, the company reported encouraging long-term data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for the given indication.\nPer management, the long-term data has bolstered the candidate's potential as a groundbreaking treatment for HAE as patients experienced durable elimination of their HAE attacks in the ongoing phase I/II study.\nThe company has completed enrollment in the phase II portion of its study. The company plans to begin a pivotal phase III study on NTLA-2002 in the HAE indication in the second half of 2024.\nThis apart, NTLA submitted a clinical trial application to initiate a first-in-human phase I study of NTLA-3001 in December 2023. The company plans to begin patient dosing later in 2024.\nThough Intellia is making good progress with its encouraging pipeline development, failure in ongoing studies will be a huge setback for the company.\nMeanwhile, several companies are also using the CRISPR/Cas9 gene editing technology to address various diseases in specific areas. Companies like Editas Medicine, CRISPR Therapeutics and Precision BioSciences are developing their respective in-vivo and ex-vivo therapies. As a result, competition in the targeted space remains an overhang for Intellia.\n\nIntellia Therapeutics, Inc. Price and Consensus\n  \nIntellia Therapeutics, Inc. price-consensus-chart | Intellia Therapeutics, Inc. Quote\n\nZacks Rank & Stocks to Consider\nIntellia currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the healthcare sector are Acrivon Therapeutics, Inc. ACRV and Aligos Therapeutics, Inc. ALGS, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nIn the past 60 days, estimates for Acrivon Therapeutics’ 2024 loss per share have narrowed from $3.42 to $2.47. Loss per share estimates for 2025 have narrowed from $3.36 to $2.55. Year to date, shares of ACRV have surged 56.9%.\nACRV’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining one occasion, the average surprise being 3.56%.\nIn the past 60 days, estimates for Aligos Therapeutics’ 2024 loss per share have narrowed from 84 cents to 73 cents, while loss per share estimates for 2025 have narrowed from 82 cents to 71 cents. Year to date, shares of ALGS have declined 23.5%.\nALGS’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, the average surprise being 7.83%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nRegeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report\nIntellia Therapeutics, Inc. (NTLA) : Free Stock Analysis Report\nAligos Therapeutics, Inc. (ALGS) : Free Stock Analysis Report\nAcrivon Therapeutics, Inc. (ACRV) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2443606711"}